Maxion Therapeutics
Engineered protein therapeutics for ion channel- and GPCR-driven diseases
Highlights
- New on EvolcAdded 2026-10-31
About Maxion Therapeutics
Maxion Therapeutics develops antibody-based protein therapeutics using its KnotBody technology, which incorporates knottins into antibody binding loops to target ion channels and GPCRs.
The company is based in London and was founded in 2020. Its registered office is in London, and its listed Cambridge address is at Unity Campus. It lists vacancies for a tissue culture technician and programme manager.
Product: KnotBody-based antibody therapeutics targeting ion channels and GPCRs.
Jobs at Maxion Therapeutics
No open positions listed right now.
More biotech & pharma companies
MC2 Therapeutics
Topical dermatology products, prescription and DermoCosmetic, for psoriasis and itchy, dry or sensitive skinNew on EvolcMdbiologics
UK healthcare company with separate websites for healthcare professionals and members of the publicYoung companyNew on EvolcMedherant
Clinical-stage pharma developing the TEPI Patch transdermal platform, starting with a testosterone patch for postmenopausal womenNew on EvolcMeiragtx
Develops genetic medicines and gene-regulation technologies for patients with rare and common diseasesNew on EvolcMestag Therapeutics
Immunology company developing first-in-class antibodies for cancer and inflammatory diseases based on fibroblast biologyNew on EvolcMetrion Biosciences
Preclinical CRO running ion channel, cardiac safety and neuroscience screening for pharma and biotech drug discoveryNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- AWS
- BambooHR
- Cloudflare
- Google Analytics 4
- Webflow